Photocarcinogenesis in mice by 4,4',6 trimethylangelicin plus UVA radiation.
The carcinogenic effect of a new monofunctional psoralen 4,4',6-trimethylangelicin (TMA) plus UVA radiation was examined in C3H/HeN mice and compared with that of the parent compound angelicin. TMA carcinogenic effects were also compared with the previously reported effects of 8-methoxypsoralen. Using 2 different doses of TMA (25 micrograms and 250 micrograms) combined with 1 J/cm2 of UVA radiation, we found that 42% and 52% of the mice (respectively) developed tumors on the treated site. A dose of angelicin (215 micrograms) equimolar to the highest dose of TMA combined with 1 J/cm2 of UVA radiation produced tumors in 28% of the mice (P greater than 0.05). All tumors were squamous cell carcinomas. No metastases were found in any of the mice. We conclude that, although TMA + UVA radiation is carcinogenic in mice, it seems to be an equally active, but less phototoxic and less carcinogenic psoralen than 8-methoxypsoralen. The parent compound angelicin is not significantly less carcinogenic, and its clinical efficacy is poor.
Alcalay
J
J
Department of Immunology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Dall'Acqua
F
F
Kripke
M L
ML
D000818:Animals; D003043:Cocarcinogenesis; D005260:Female; D011564:Furocoumarins / Q000633:toxicity*; D051379:Mice; D009381:Neoplasms, Radiation-Induced / Q000209:etiology* / Q000473:pathology; D011701:PUVA Therapy / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000473:pathology
D011564:Furocoumarins; C041621:4,4',6-trimethylangelicin